Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.145
-0.045 (-1.07%)
Dec 26, 2025, 2:03 PM EST - Market open
Precigen Revenue
Precigen had revenue of $2.92M in the quarter ending September 30, 2025, with 206.61% growth. This brings the company's revenue in the last twelve months to $6.31M, up 59.20% year-over-year. In the year 2024, Precigen had annual revenue of $3.93M, down -36.95%.
Revenue (ttm)
$6.31M
Revenue Growth
+59.20%
P/S Ratio
197.72
Revenue / Employee
$44,119
Employees
143
Market Cap
1.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
| Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PGEN News
- 4 weeks ago - Precigen Is Still A Buy After The Papzimeos Rally - Seeking Alpha
- 6 weeks ago - Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PRNewsWire
- 7 weeks ago - Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 - PRNewsWire
- 2 months ago - Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 4 months ago - Precigen Announces Up to $125 Million Non-Dilutive Financing - PRNewsWire
- 4 months ago - Precigen, Inc. - Special Call - Seeking Alpha
- 4 months ago - Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright - PRNewsWire